Fate Therapeutics, Inc. (NASDAQ:FATE) Posted Basic Consolidated EPS Of $-1.1769

0

Fate Therapeutics, Inc. (NASDAQ:FATE) annual basic consolidated EPS was $-1.1769 for the period ended 2015-12-31. The basic consolidated EPS was $-1.1769 for the quarter ended 2015-12-31.

EPS from continuing operations

Fate Therapeutics, Inc. (NASDAQ:FATE)’s basic EPS from continuing operations was $-1.1769 for the fiscal year 2015-12-31. For the quarter ended 2015-12-31 it stood at $-1.1769

EPS contribution from parent

From the parent company Fate Therapeutics, Inc. (NASDAQ:FATE) posted basic EPS of $-1.1769 for the fiscal ended 2015-12-31. For the quarter that ended on 2015-12-31 the figure stood at $-1.1769.

Basic net EPS

The Basic net EPS of Fate Therapeutics, Inc. (NASDAQ:FATE) was $-1.18 for the period ended 2015-12-31. The figure stood at $-1.18 for the quarter that ended 2015-12-31.

Consolidated diluted EPS

The consolidated diluted EPS for the fiscal year 2015-12-31 stood at $-1.1769. While the figure for the quarter ended 2015-12-31 stood at $-1.1769.

Basic diluted EPS

The diluted EPS from continuing operation of Fate Therapeutics, Inc. (NASDAQ:FATE) stood at $-1.1769 for the fiscal 2015-12-31. The figure for the quarter ended 2015-12-31 stood at $-1.1769

Net diluted EPS

The Net diluted EPS was $-1.18 for the fiscal 2015-12-31. The figure for the quarter ended 2015-12-31 stood at $-1.18.

Diluted EPS from parent

Fate Therapeutics, Inc. (NASDAQ:FATE) diluted EPS from the parent company for the fiscal 2015-12-31 was $-1.1769. The figure for the quarter ended 2015-12-31 was $-1.1769

The net basic EPS was $-1.27 for fiscal 2015-12-31. The figure for the quarter ended 2015-12-31 was $-1.27.

1 Chart Pattern Every Investor Should Know

This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...

Click Here to See This Now.

(Visited 1 times, 1 visits today)